| Previous Close | 48.95 |
| Open | 49.32 |
| Bid | 45.94 x 100 |
| Ask | 49.00 x 100 |
| Day's Range | 47.61 - 49.32 |
| 52 Week Range | 41.38 - 53.50 |
| Volume | 63,867 |
| Avg. Volume | 108,185 |
| Market Cap | 701.88M |
| Beta | 1.11 |
| PE Ratio (TTM) | 23.12 |
| EPS (TTM) | 2.07 |
| Earnings Date | Jul 26, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.50 |
- Zacks•3 days ago
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics
- Business Wire•4 days ago
Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC
Anika Therapeutics, Inc. , a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that it will receive a $5 million milestone payment under the terms of the Company’s license agreement with its U.S.
- American City Business Journals•4 days ago
Anika pays former medical chief $350K to thwart possible lawsuit
Back in January, Bedford-based Anika Therapeutics disclosed in a one-sentence federal filing that one of its top executives, chief medical officer Stephen Mascioli, had left the company after less than a year on the job. Anika (ANIK) said Friday that it had agreed to pay Mascioli $350,000 for “alleged damages and attorneys’ fees,” including $250,000 for alleged lost wages. While the filing did not disclose the nature of Mascioli’s allegations, it said that he had agreed not to pursue any legal action against Anika, including potential claims for age discrimination and retaliation.
